Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Arcutis Biotherapeutics: Clinical Trials & FDA Approval Profile

Arcutis Biotherapeutics (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 1 active protocols (0 recruiting now), 19 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.8%
Median Closed Enrollment vs National (145 pts)335 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Arcutis Biotherapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)1 (0)
Completed vs Stopped Early19 / 1 (4.8%)
Median Closed Actual Enrollment335 participants
Physical Hospital Site Disclosure98.2% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Arcutis Biotherapeutics
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05028582Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)Phase IIICOMPLETED
NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)Phase IIICOMPLETED
NCT04286607Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPhase IIICOMPLETED
NCT04091646Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisPhase IICOMPLETED
NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Arcutis Biotherapeutics Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI